Greifswald, Germany – Cheplapharm Arzneimittel GmbH (“we, “us”, or the “Company”) announces that it has launched an offering of €1,000,000,000 (equivalent) aggregate principal amount of senior secured notes due 2028 (the “Notes”). The Notes comprise a euro-denominated tranche and U.S. dollar denominated tranche and are being offered only to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside the United States in offshore transactions in reliance on Regulation S under the Securities Act. The interest rate, offering price and certain other terms will be determined at the time of pricing of the Notes, subject to market conditions.
The Company intends to use the proceeds from the offering of the Notes, together with the proceeds of a drawdown under its revolving credit facility and cash on hand to (i) pay the purchase price for three portfolios of pharmaceutical products it agreed to acquire in between June and September 2020 and the acquisition of worldwide marketing authorizations for Rivotril® as well as (ii) costs and expenses related to the foregoing.